Efficacy and safety of cisplatin plus capecitabine for patients with metastatic triple negative breast cancer progressing after anthracycline and taxane treatment / 中华肿瘤杂志
Chinese Journal of Oncology
;
(12): 938-941, 2015.
Article
in Chinese
| WPRIM
| ID: wpr-304471
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the efficacy and safety of cisplatin and capecitabine combination (XP) therapy for patients with metastatic triple negative breast cancer (TNBC) progressing after anthracycline and taxane treatment.</p><p><b>METHODS</b>Twenty-nine metastatic TNBC patients were prospectively enrolled to receive capecitabine (1, 000 mg/m(2) twice daily on days 1-14) and cisplatin (75 mg/m(2) on day 1) , repeated every 3 weeks.</p><p><b>RESULTS</b>With a median of 6 cycles of XP, all 29 patients were evaluable for response, including 18 PR (62.1%), 6 SD (20.7%), 5 PD (17.2%) and no CR. The response rate was 62.1%. Patients with earlier stage at diagnosis (stage I to IIIA), longer post-operative disease free survival (>2 years) and less metastatic sites (≤ 3) obtained significantly higher response rate than patients with later stage at diagnosis (stage IIIB to IV), shorter post-operative disease free survival (≤ 2 years) and more metastatic sites (>3). The leading side effects were grade 1/2 gastrointestinal and hematological toxicities. Grade 3/4 toxicities included neutropenia (34.5%), leukocytopenia (31.0%), anemia (6.9%), thrombocytopenia (3.4%), nausea/vomiting (20.7%), stomatitis (3.4%), and hand-foot syndrome (3.4%).</p><p><b>CONCLUSION</b>Cisplatin and capecitabine combination therapy is an active and well-tolerated doublet treatment in metastatic TNBC patients progressing after anthracycline and taxane treatments.</p>
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Pathology
/
Bridged-Ring Compounds
/
Antineoplastic Combined Chemotherapy Protocols
/
Prospective Studies
/
Cisplatin
/
Treatment Outcome
/
Disease-Free Survival
/
Anthracyclines
/
Taxoids
/
Therapeutic Uses
Type of study:
Observational study
Limits:
Female
/
Humans
Language:
Chinese
Journal:
Chinese Journal of Oncology
Year:
2015
Type:
Article
Similar
MEDLINE
...
LILACS
LIS